Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer


Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer


Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. It is not yet known whether anastrozole is more effective with or without fulvestrant in treating breast cancer.


This randomized phase III trial is studying giving anastrozole together with fulvestrant to see how well it works compared to anastrozole alone as first-line therapy in treating postmenopausal women with metastatic breast cancer.

Study Status: Active, not recruiting


Condition Intervention Phase
Breast Cancer Drug: anastrozole
Drug: fulvestrant
Phase 3

Verified by Southwest Oncology Group May, 2013

Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group identifier: NCT00075764

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Beachwood Family Health and Surgery Center
Beachwood, Ohio 44122
United States

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States

Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States

Rita S. Mehta, MD., Study Chair
Theodore A. Vandenberg, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site